| Balance sheet (USD) | Q2 2026 ended May 31, 2026 | Q1 2026 ended Feb 28, 2026 | Q4 2025 ended Nov 30, 2025 | Q3 2025 ended Aug 31, 2025 | Q2 2025 ended May 31, 2025 | Q1 2025 ended Feb 28, 2025 | Q4 2024 ended Nov 30, 2024 | Q3 2024 ended Aug 31, 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 67.69M | 71.19M | 246.96M | 78.44M | 84.26M | 75.92M | 110.00M | 99.04M |
| Receivables | 19.00M | 0 | ||||||
| Total current assets | 456.48M | 554.39M | 606.82M | 440.60M | 515.33M | 563.70M | 619.39M | 456.04M |
| Property, plant and equipment | 20.01M | 21.70M | 22.49M | 20.50M | 18.77M | 18.45M | 17.76M | 17.07M |
| Total assets | 535.54M | 636.13M | 688.13M | 522.47M | 591.55M | 615.04M | 669.34M | 513.60M |
| Accounts payable | 12.21M | 10.29M | 11.21M | 8.61M | 5.95M | 8.40M | 11.48M | 3.92M |
| Total current liabilities | 72.02M | 92.20M | 86.47M | 82.35M | 75.61M | 89.99M | 95.85M | 86.30M |
| Total liabilities | 132.91M | 155.24M | 149.39M | 150.22M | 143.95M | 134.13M | 142.35M | 136.74M |
| Retained earnings | -1.18B | -1.09B | -1.00B | -925.00M | -838.58M | -795.12M | -738.77M | -680.22M |
| Shareholders' equity | 402.63M | 480.89M | 538.75M | 372.25M | 447.60M | 480.92M | 526.99M | 376.86M |
From Nurix Therapeutics, Inc.'s 10-K and 10-Q filings with the SEC. Fourth quarters, and quarters where the company only reported year-to-date totals, are worked out by subtracting the earlier quarters. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read balance sheet or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.